{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Xencor, Inc. technically bullish or bearish?
As of October 31, 2025, Xencor, Inc. shows a mildly bullish technical trend despite underperforming the S&P 500, with mixed signals from various indicators suggesting caution.
Xencor Stock Forms Golden Cross, Signaling Potential Bullish Breakout Ahead
Xencor, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock has risen 4.1% today and 11.36% over the past week, despite a challenging year-to-date performance. Mixed technical indicators suggest a complex outlook as the company seeks to attract investor interest.
Is Xencor, Inc. technically bullish or bearish?
As of October 31, 2025, Xencor, Inc. shows a mildly bullish trend based on weekly indicators, despite significant underperformance compared to the S&P 500 and mixed signals in longer time frames.
Is Xencor, Inc. technically bullish or bearish?
As of October 31, 2025, Xencor, Inc. shows a mildly bullish technical trend, supported by weekly MACD and moving averages, but caution is advised due to mixed longer-term signals and significant underperformance compared to the S&P 500.
Xencor Stock Soars to Day High with 13.44% Intraday Surge
Xencor, Inc. has seen a notable increase in its stock performance today, reaching an intraday high amid a challenging market. Despite recent gains, the company has faced longer-term declines. Positive sales growth was reported, but profitability metrics remain concerning, with institutional holdings at 100%.
Xencor Stock Hits Day Low of $11.17 Amid Price Pressure
Xencor, Inc. faced a notable stock decline today, reaching an intraday low amid ongoing market challenges. Over the past year, the company has struggled significantly, with a total return of -40.89%. Despite a recent increase in net sales, profitability metrics remain negative, indicating ongoing difficulties in generating shareholder value.
Xencor Stock Soars 7.14% to Intraday High Amid Strong Performance
Xencor, Inc. has seen a significant increase in its stock price today, contrasting with a decline in the S&P 500. The company has shown strong weekly and monthly gains, although it faces challenges with longer-term performance metrics. Positive sales growth was reported recently, supported by high institutional ownership.
Is Xencor, Inc. technically bullish or bearish?
As of September 2, 2025, Xencor, Inc. is in a mildly bearish trend, with mixed technical indicators showing short-term strength but a year-to-date return of -56.35% compared to the S&P 500's 12.22%.
Is Xencor, Inc. overvalued or undervalued?
As of February 23, 2023, Xencor, Inc. is considered overvalued with a risky valuation grade due to negative financial metrics, including a Price to Book Value of 1.07, an EV to Sales ratio of 2.95, a troubling ROCE of -50.84%, and a year-to-date stock return of -56.35% compared to the S&P 500's gain of 12.22%.
Is Xencor, Inc. overvalued or undervalued?
As of February 23, 2023, Xencor, Inc. is considered overvalued and risky due to poor financial metrics and a year-to-date stock performance decline of 63.40%, significantly underperforming the S&P 500.
Is Xencor, Inc. technically bullish or bearish?
As of June 6, 2025, Xencor, Inc. shows a mildly bearish trend due to daily moving averages and weekly Bollinger Bands indicating bearish momentum, despite mixed signals from the MACD and RSI across different time frames.
Who are in the management team of Xencor, Inc.?
As of March 2022, Xencor, Inc.'s management team includes Dr. Bassil Dahiyat as President and CEO, with Dr. A. Bruce Montgomery as Lead Independent Director and other Independent Directors: Dr. Ellen Feigal, Dr. Kevin Gorman, Mr. Kurt Gustafson, and Mr. Yujiro Hata.
What does Xencor, Inc. do?
Xencor, Inc. is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for severe diseases. As of March 2025, it reported net sales of $33 million and a net loss of $49 million, with a market cap of $591.43 million.
How big is Xencor, Inc.?
As of Jun 18, Xencor, Inc. has a market capitalization of 591.43 million and reported net sales of 127.23 million with a net profit of -211.05 million over the latest four quarters. Shareholder's funds are at 677.61 million and total assets at 951.95 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
